secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILENT TECHNOLOGIES, INC. (A)
CIK:        0001090872
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001090872-24-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agilent moves Cell Analysis Div. to D&G segment; recasts FY21-23 segment data
-----------------------------------------------------------------------------

- Cell Analysis Division moved from LSAG to Diagnostics & Genomics Group (DGG) effective Q1 FY24.
- Recast segment financials for FY21-23: LSAG FY23 revenue $3.51B, DGG $1.755B, CrossLab $1.568B.
- LSAG FY23 operating margin 29.9%; DGG 20.7%; CrossLab 29.5%.
- Prior periods restated; new reporting structure begins with quarter ending Jan 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1090872/000109087224000003/0001090872-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1090872/000109087224000003/a-20240105.htm
  HTML page:      https://secwatch.observer/filing/0001090872-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer